A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–130
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female participants must be ≥ 18 years old
Mean sitting systolic blood pressure on automated office blood pressure measurement ≥ 140 mmHg and \< 170 mmHg at Screening
Fulfil at least 1 of the following 2 criteria:
1. uHTN subpopulation: have a stable regimen of 2 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator
2. rHTN subpopulation: have a stable regimen of ≥ 3 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator
Estimated glomerular filtration rate ≥ 45 mL/min/1.73m2 at Screening
Serum potassium (K+) level ≥ 3.5 and \< 5.0 mmol/L at Screening
Randomisation Criterion:
Sitting systolic blood pressure on attended automated office blood pressure measurement of ≥ 135 mmHg at the Baseline Visit
You may not be if
Mean sitting systolic blood pressure on attended automated office blood pressure measurement ≥ 170 mmHg
Mean seated diastolic blood pressure on attended automated office blood pressure measurement ≥ 110 mmHg
Serum sodium level \< 135 mmol/L at Screening
Has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation
New York Heart Association functional heart failure class IV at Screening
Persistent atrial fibrillation
Clareo Health | A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
